Maravai LifeSciences (MRVI) vs. Its Peers Financial Analysis

Maravai LifeSciences (NASDAQ:MRVI) is one of 109 public companies in the “Life Sciences Tools & Services” industry, but how does it weigh in compared to its competitors? We will compare Maravai LifeSciences to similar businesses based on the strength of its dividends, risk, valuation, profitability, earnings, institutional ownership and analyst recommendations.

Profitability

This table compares Maravai LifeSciences and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-30.83%	-12.23%	-6.43%
Maravai LifeSciences Competitors	-538.54%	-166.23%	-13.47%

Earnings & Valuation

This table compares Maravai LifeSciences and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Maravai LifeSciences	$208.78 million	-$130.77 million	-17.29
Maravai LifeSciences Competitors	$2.33 billion	$55.11 billion	-7.75

Maravai LifeSciences’ competitors have higher revenue and earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Maravai LifeSciences has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, Maravai LifeSciences’ competitors have a beta of 0.94, indicating that their average stock price is 6% less volatile than the S&P 500.

Institutional and Insider Ownership

50.2% of Maravai LifeSciences shares are held by institutional investors. Comparatively, 54.2% of shares of all “Life Sciences Tools & Services” companies are held by institutional investors. 2.5% of Maravai LifeSciences shares are held by company insiders. Comparatively, 14.8% of shares of all “Life Sciences Tools & Services” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Maravai LifeSciences and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	1	1	2	1	2.60
Maravai LifeSciences Competitors	951	3172	5504	178	2.50

Maravai LifeSciences presently has a consensus price target of $7.38, suggesting a potential downside of 0.78%. As a group, “Life Sciences Tools & Services” companies have a potential downside of 2.24%. Given Maravai LifeSciences’ stronger consensus rating and higher possible upside, equities analysts plainly believe Maravai LifeSciences is more favorable than its competitors.

Summary

Maravai LifeSciences competitors beat Maravai LifeSciences on 7 of the 13 factors compared.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.